We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Orl6.0
Orlistat Research
Mostly mechanism / observational
50 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Orlistat studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1998–2026 with a typical study size of 688 participants.
Based on 49 studies · 9 meta-analyses · 10 RCTs · 5,293 total participants
Confidence
High confidence
By outcome
Weight managementAbout 2.6–2.9 kg more weight loss than placebo at one year; 44% of users reach ≥5% body-weight loss vs 23% on placebo · 4-12 weeks
Mostly mechanism / observational38 studies
Glucose & metabolicIn obese type 2 diabetes on sulfonylureas, significant HbA1c and fasting-glucose reduction with sulfonylurea dose reductions · 3-6 months · Lower total and LDL cholesterol, lower fasting insulin, and a 37.3% relative reduction in new type 2 diabetes over 4 years — but only in those with impaired glucose tolerance at baseline, not across obese adults generally · 6-12 months
Too few graded studies11 studies
Safety profile
Too few graded studies9 studies
Cholesterol & lipids
Too few graded studies8 studies
Heart & blood pressure
Too few graded studies5 studies
Liver health
Mostly mechanism / observational5 studies
Women's health
Too few graded studies4 studies
Recovery
Too few graded studies2 studies
5 more outcomes with fewer studies not shown.
Active research area
34 studies in the last 5 years · Latest meta-analysis: 2026
199820122026
1Meta-AnalysisRetracted2022
In plain English: In adults with overweight and obesity, phentermine-topiramate and GLP-1 receptor agonists proved the best drugs in reducing weight; of the GLP-1 agonists, semaglutide might be the most effective.
Shi Q et al. · Lancet (London, England) (2022)
In adults with overweight and obesity, phentermine-topiramate and GLP-1 receptor agonists proved the best drugs in reducing weight; of the GLP-1 agonists, semaglutide might be the most effective.
In plain English: After 4 years' treatment, the cumulative incidence of diabetes was 9.0% with placebo and 6.2% with orlistat, corresponding to a risk reduction of 37.3% (P = 0.0032).
Torgerson, Hauptman, Boldrin, Sjöström · Diabetes Care (2004)
4-year double-blind trial randomising 3,305 obese patients (BMI ≥30) to lifestyle changes plus orlistat 120 mg or placebo three times daily
Cumulative 4-year diabetes incidence 6.2% with orlistat vs 9.0% with placebo — a 37.3% relative risk reduction (P = 0.0032)
Mean 4-year weight loss 5.8 kg with orlistat vs 3.0 kg with placebo (P < 0.001); with baseline-carried-forward for dropouts, 3.6 vs 1.4 kg (P < 0.001)
In plain English: During the first year orlistat-treated subjects lost more weight (mean ± SEM, 8.76±0.37 kg) than placebo-treated subjects (5.81±0.67 kg) (P<.001).
2-year randomised, double-blind, placebo-controlled trial at 18 US research centres; 1,187 obese adults (BMI 30–43) entered and 892 were randomised, with 223 placebo- and 657 orlistat-treated subjects in the intent-to-treat analysis
Year 1: 8.76 ± 0.37 kg weight loss with orlistat 120 mg three times daily vs 5.81 ± 0.67 kg with placebo (P<.001)
Year 2 regain: 3.2 kg (35.2% regain) on orlistat 120 mg tid vs 4.26 kg (51.3%) on 60 mg tid vs 5.63 kg (63.4%) on placebo (P<.001) — the dose comparison behind the 120 mg Rx vs 60 mg OTC strengths
In plain English: Our findings suggest that orlistat meaningfully reduces BMI but is associated with decreased HDL-C, which may be undesirable given HDL-C's protective role in cardiovascular health.
Khodadadiyan A, Khazraei Y, Kamali M, Kolaei K, Aminzadeh P, Yazdanpanah G, Shams A, Feili M, Ghaffari M, Hosseini M, Bazrafshan M, Drissi HB, Arzhangzadeh A. · Journal of obesity (2026)
Orlistat reduced body mass index (BMI) (SMD [95% CI]: -0.30 [-0.58, -0.03], p value (heterogeneity) = 0.026), and also it was associated with a decrease in high-density lipoprotein cholesterol (SMD (95% CI): -0.31 [-0.48, -0.13], p value (heterogeneity) = 0.436).
The secondary analysis demonstrated that follow-up duration accounted for 30% of TG heterogeneity, suggesting a small but significant decline in orlistat's TG-lowering effect over time (slope: -0.1239; 95% CI: -0.2355, -0.0123; p value = 0.0295).
Evidence for reductions in TG and WC is uncertain: the primary meta-analysis showed no statistically significant effects, whereas trim-and-fill sensitivity analysis suggested potential reductions.
In plain English: Further randomized controlled trials are necessary to ascertain its long-term impact on prognosis.
Zhang L, Meng C, Zhang F, Jia X, Xie J, Zhu Y, Zhou X, Liu P. · Journal of pediatric endocrinology & metabolism : JPEM (2025)
The orlistat group reduced BMI compared to placebo in the short term (MD=-0.73, 95 % CI: -1.44 to -0.02, p=0.04, I 2 =73 %) but appeared to have little effect in the long term (MD=-1.72, 95%CI: -3.55 to 0.12, p=0.07, I 2 =84 %).
Conclusions Orlistat has been linked to alter lipid levels in obese or overweight children.
However, the evidence regarding its efficacy in reducing BMI is inconclusive, with inconsistent findings across short and long-term studies.
In plain English: Compared with placebo, orlistat reduced weight by 2.9 kg (95% confidence interval 2.5 kg to 3.2 kg).
Rucker, Padwal, Li, Curioni, Lau · BMJ (2007)
Updated meta-analysis of double-blind randomised placebo-controlled trials of approved anti-obesity drugs lasting one year or longer; 30 trials met inclusion, of which 16 were orlistat trials (n=10,631 participants)
Orlistat reduced weight by 2.9 kg vs placebo (95% CI 2.5 to 3.2 kg) — smaller than sibutramine (4.2 kg) and rimonabant (4.7 kg) in the same analysis
Patients on active drug were significantly more likely to achieve 5% and 10% weight-loss thresholds
In plain English: A median 23% of placebo participants had at least 5% weight loss vs ... 44% taking orlistat (OR, 2.70; 95% CrI, 2.34-3.09; SUCRA, 0.22).
Bayesian network meta-analysis of 28 randomised trials in 29,018 overweight or obese adults comparing the five FDA-approved long-term weight-loss agents
Orlistat: 44% of patients achieved ≥5% weight loss vs a 23% placebo median (OR 2.70, 95% CrI 2.34–3.09), with the lowest SUCRA ranking (0.22) of the five agents
Excess weight loss with orlistat was 2.6 kg vs placebo (95% CrI −3.04 to −2.16), compared with 8.8 kg for phentermine-topiramate and 5.3 kg for liraglutide
In plain English: In prediabetic people, the orlistat can control weight, reduce the fasting blood glucose and the 2 hour postprandial blood glucose, and then delay the progression of diabetes.
Gao Z, Huang M, Wang J, Jia H, Lv P, Zeng J, Ti G. · Medicine (2024)
The results indicated that the orlistat can reduce the fasting blood glucose [relative risk (RR) = -2.18, 95% confidence intervals (CI) (-2.471, -1.886)], as well as the 2 hour postprandial blood glucose [RR = -1.497, 95% CI (-1.811, -1.183)].
Furthermore, it can prevent the impaired glucose tolerance patients to type 2 diabetes mellitus [RR = 0.605, 95% CI (0.462, 0.791)], and reversal the impaired glucose tolerance [RR = 2.092, 95% CI (1.249, 3.503)].
Conclusions In prediabetic people, the orlistat can control weight, reduce the fasting blood glucose and the 2 hour postprandial blood glucose, and then delay the progression of diabetes.
In plain English: From the start of lead-in to the end of year 1, the orlistat group lost, on average, more bodyweight than the placebo group (10.2% [10.3 kg] vs 6.1% [6.1 kg]; LSM difference 3.9 kg [p<0.001] from randomisation to the end of year 1).
743 obese patients (BMI 28–47) entered a 4-week placebo lead-in at 15 European centres; 688 were randomised double-blind to orlistat 120 mg three times a day or placebo for 1 year on a 600 kcal/day-deficit diet, then reassigned for a second 52-week weight-maintenance period
Year 1: 10.2% (10.3 kg) body-weight loss with orlistat vs 6.1% (6.1 kg) with placebo; least-squares-mean difference 3.9 kg from randomisation (p<0.001)
Year 2: patients continuing orlistat regained on average half as much weight as those switched to placebo (p<0.001); those switched from placebo to orlistat lost a further 0.9 kg vs a mean 2.5 kg regain on continued placebo (p<0.001)
In plain English: Combining standard therapy with GLP-1 receptor agonists offers superior efficacy in improving metabolic and hormonal outcomes in women with PCOS.
Bo Y, Zhao J, Liu C, Yu T. · BMC women's health (2025)
The combination of standard therapy with GLP-1 receptor agonists significantly reduced BW (MD= -3.44; 95% CI= -6.20 to -0.67), BMI (MD= -2.05; 95% CI= -3.55 to -0.55), and WC (MD= -4.39; 95% CI= -6.75 to -2.02) compared to standard therapy alone.
Orlistat significantly lowered testosterone (SMD= -2.16; 95% CI= -3.84 to -0.48) and increased HDL-C levels (SMD = 0.90; 95% CI = 0.02 to 1.79) compared to placebo.
The combination therapy also reduced HOMA-IR (MD= -1.29; 95% CI= -2.38 to -0.21) and FBG (SMD= -1.80; 95% CI= -3.04 to -0.55) compared to placebo.
In plain English: There is a need for high-quality adequately powered RCTs on intentional weight loss in HFpwO with survival and hospitalization outcomes.
Peck KH et al. · European journal of heart failure (2024)
There is a need for high-quality adequately powered RCTs on intentional weight loss in HFpwO with survival and hospitalization outcomes.
All forms of weight loss intervention studied in this review were likely to result in significant weight loss, improved symptoms and QOL.
Careful monitoring is required due to an increase in certain adverse events. [Correction added on 11 September 2024, after first online publication: The sub-headings 'Aims', 'Methods and results' and 'Conclusion' have been added in this version.].
In plain English: This study has concluded that Orlistat can be used for significant improvement in lipid profile.
Alanazi J et al. · European review for medical and pharmacological sciences (2022)
The study found that the Orlistat group has significant improvement (p<0.05) more improvement in LDL cholesterol, HDL cholesterol, Total cholesterol, LDL/HDL Ratio and Triglycerides, while BMI and systolic blood pressure did not show a significant difference between placebo and Orlistat group.
This study has concluded that Orlistat can be used for significant improvement in lipid profile.
The study also found that Orlistat may not have a significant effect on reducing BMI and blood pressure without adequate lifestyle modification.
In plain English: This review has summarized, side-by-side, the various outcomes of obesity interventions on mental health.
Osborne D, Abdelgadir E. · International journal of obesity (2005) (2026)
Mental health is a critical yet underprioritized element of obesity management.
The current evidence suggests that most weight loss interventions are psychologically safe or beneficial, but long-term data remain limited, particularly for GLP-1 receptor agonists.
Future randomized trials must incorporate mental health as a prespecified outcome, and individualized treatment approaches should integrate psychological support to optimize long-term outcomes.
In plain English: The role of these agents in PCOS should be a high priority for future research.
Goldberg A, Graca S, Liu J, Rao V, Witchel SF, Pena A, Li R, Mousa A, Tay CT, Pattuwage L, Teede H, Yildiz BO, Ee C. · Obesity reviews : an official journal of the International Association for the Study of Obesity (2024)
On meta-analysis, no differences were identified between exenatide versus metformin for anthropometric, biochemical hyperandrogenism, and metabolic outcomes, other than lower fasting blood glucose more with metformin than exenatide (MD: 0.10 mmol/L, CI 0.02-0.17, I 2 = 18%, 2 trials).
Orlistat + COCP did not improve metabolic outcomes compared with COCP alone (fasting insulin MD: -8.65 pmol/L, -33.55 to 16.26, I 2 = 67%, 2 trials).
Published data examining the effects of anti-obesity agents in women with PCOS are very limited.
In plain English: Liraglutide effectively results in clinically significant weight loss, achieves expected weight loss targets, and improves metabolic parameters in real-world clinical practice.
Hepşen S et al. · European journal of medical research (2025)
At least one side effect was observed in 48% of the patients, with nausea and vomiting being the most common.
The most frequent reason for discontinuing treatment was the cost of the medication (42.6%).
Among the entire cohort, 76.4% and 40.9% of patients achieved a 5% and 10% weight loss target, respectively.
In plain English: An increasing proportion of patients gained weight over time, combined with low AOM use, emphasizing the need for weight-loss interventions in this population.
Osterland A et al. · Current medical research and opinion (2022)
A subset of 22,712 patients was continuously enrolled for the entire study period (mean age: 57.2) and were primarily white (83.3%) and commercially insured (54.3%).
Most patients were categorized as overweight (40.1%) or obesity class I (32.5%) at baseline.
At years 1 and 4 post-index, patients who maintained index weight (±3%) was 56.2% and 37.0%, respectively, whereas weight gain (≥3% increase) was 23.7% and 33.3%, respectively.
In plain English: After 1 year of treatment, the orlistat group lost 6.2 ± 0.45% (mean ± SEM) of initial body weight vs. 4.3 ± 0.49% in the placebo group (P < 0.001).
Multicentre 57-week randomised double-blind placebo-controlled trial of orlistat 120 mg three times daily in 391 obese adults with type 2 diabetes stable on oral sulfonylureas
Weight loss 6.2 ± 0.45% vs 4.3 ± 0.49% of initial body weight (P < 0.001); twice as many orlistat patients lost ≥5% of body weight (49% vs 23%, P < 0.001)
Significant improvement in glycaemic control — decreases in HbA1c (P < 0.001) and fasting plasma glucose (P < 0.001) — with dosage reductions of oral sulfonylurea (P < 0.01)
In plain English: This review summarizes studies about structure, mechanistic approach of pancreatic lipase enzyme while emphasizing on the various synthetic pancreatic lipase inhibitors with their structure activity relationship (SAR).
Kumar A et al. · Life sciences (2021)
Hence, the modulation of human pancreatic lipase may represent a new insight in the discovery of a number of therapeutics that can inhibit the absorption of fat in body and can be used in obesity and other related metabolic disorders.
Even, the only Food and drug administration (FDA) approved antiobesity drug, orlistat, is also an inhibitor of pancreatic lipase.
This review summarizes studies about structure, mechanistic approach of pancreatic lipase enzyme while emphasizing on the various synthetic pancreatic lipase inhibitors with their structure activity relationship (SAR).
In plain English: The findings of our study reported that orlistat improved NAFLD-related factors and metabolic syndrome-related factors compared to placebo for 12 weeks.
Zahmatkesh A et al. · European journal of pediatrics (2024)
The findings of our study reported that orlistat improved NAFLD-related factors and metabolic syndrome-related factors compared to placebo for 12 weeks.